COLLEEN PLANCHON: Open Payments
NPI 1497183446 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,268 in 31 payments from 14 companies in 2025. Trend: 2023 $1,194 · 2024 $1,232 · 2025 $1,268
Food & beverage: $1,188Education: $80
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 4 | $261 |
| BridgeBio Pharma, Inc. | 4 | $230 |
| Novo Nordisk Inc | 4 | $198 |
| AstraZeneca Pharmaceuticals LP | 3 | $174 |
| Amgen Inc. | 3 | $75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $55 |
| Novartis Pharmaceuticals Corporation | 2 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Abbott Laboratories | 2 | $45 |
| Baxter Healthcare | 1 | $38 |
Products named: Attruby, WAINUA, Wegovy, OPSUMIT, UPTRAVI, REPATHA, JARDIANCE, LEQVIO.
Industry payments across RI — which companies pay providers there.
